Parenteral Drugs Market to Exhibit 6% CAGR, on Back of Surging Demand for Self-administered Drugs Finds Fact.MR
Click HERE to Get Synopsis of the Report- https://www.factmr.com/report/3189/parenteral-drug-market
Reports at discounted rates for new entrants!!! Purchase ASAP before the offer ends!!!
Self-administered drugs through pre-filled syringes offer opportunities to reduce consumer spending on caregiver fees. Furthermore, manufacturers are gaining sharper profit margins with the introduction of this drug delivery medium in their portfolio. On this backdrop, the global parenteral drugs market estimated at US$ 451 Bn in 2019, is projected to witness moderate growth during the forecast period (2019 – 2029).
For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=3189
Drugs for cancer are always short in supply in countries where the market is monopolistic and access to such medicines is dominated by a single player. Rising prevalence of chronic illnesses such as cancer, cardiovascular diseases, and diabetes, across the globe has been the prime revenue driver for parenteral drugs and this trend is not likely to abate any time in the foreseeable future.
Key Takeaways of Parenteral Drugs Market Study
By product type, monoclonal antibodies segment accounts for maximum market share in terms of revenue in the parenteral drugs market. This is primarily attributed to the rising adoption of biologics and subsequent rise in the number of biologics approved for marketing.
North America and Europe collectively hold over 60% of the parenteral drugs market share owing to the rise in new product launches in the regions.
Hospital pharmacies segment is expected to be the dominant distribution channel in the parenteral drugs market.
The parenteral drugs market is highly fragmented. Some of the prominent parenteral drug manufacturers include, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Novartis AG, and Pfizer Inc., among many others.
Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=3189
“Patent expiration of branded products and fewer new product launches have resulted in the rise of generic versions of drugs, and in the emergence of a number of players in the market – this factor has intensified total parenteral drugs sales,” says a Fact.MR analyst.
Increased Research Funding to Drive Parenteral Drugs Market Growth
Research funding has surged significantly in recent years, which has resulted in an increase in the number of projects undertaken as well as newly employed personnel for the same. The funding for research comes from governments, private players, and other commercial entities. For instance,
In 2017, the National Cancer Institute (NCI) received over US$ 5.6 billion for research initiatives, which reflects a 7% increase as compared to 2016.
Similarly, in 2018, in the U.S., the Omnibus Appropriations bill that provided additional funding of US$ 3 billion for the NIH (National Institutes of Health) was passed, which is the highest increase in NIH funding in the past 15 years. This boost in funding, which brings the total NIH investment to US$ 37.1 billion for FY 2018, is expected to speed up cancer research in the coming years.
The expected trend indicates a significant rise in NIH funding in the fiscal year 2017 – 2018. In the future, investments in R&D are likely to increase in all countries across the world, especially in countries such as China and Brazil.
Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/3189/S
Looking for More Information?
The research study on parenteral drugs market by Fact.MR incorporates an unbiased assessment of key demand-driving factors and trends, which have shaped the landscape of parenteral drugs over 2014 – 2018 and includes a detailed assessment of key parameters that are anticipated to exert influence over 2019 – 2029. Market statistics have been presented on the basis of product type (monoclonal antibodies, immunoglobulin, cytokines, indulin, peptide harmones, blood factors, peptide antibiotics, vaccines, small molecule antibiotics, chemotherapy agents, and others), application (oncology, infectious diseases, diabetes, hormonal disorders, musculoskeletal disorders, CNS diseases, pain management and cardiovascular diseases), route of administration (intravenous, intramuscular and subcutaneous), and distribution channel (hospital pharmacies, retail pharmacies, drug stores and online pharmacies) across seven major regions.
For More Insights: https://www.biospace.com/article/rising-cases-of-cardiovascular-diseases-fuelling-fractional-flow-reserve-computed-tomography-ffr-ct-demand-fact-mr/
US Sales Office:
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email : firstname.lastname@example.org
Website : https://www.factmr.com
Research Insight: https://www.factmr.com/report/3189/parenteral-drug-market
Content Source: https://www.factmr.com/media-release/1226/global-parenteral-drug-market
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions.
We have offices in US and Dublin, whereas our global headquarter is in Dubai.While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise.
Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.
Reach out to us with your goals, and we’ll be an able research partner.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parenteral Drugs Market to Exhibit 6% CAGR, on Back of Surging Demand for Self-administered Drugs Finds Fact.MR here
News-ID: 2279984 • Views: 254
More Releases from Fact.MR
Organic Sulfur Market Global Demand, Growth, Opportunities, Top Key Players and …
Fact.MR has adopted multi-disciplinary approach to shed light on the keyword during the historical period. The study presents a deep-dive assessment of the current growth dynamics, major avenues in the estimation year, and key prospects over the forecast period 2018-2028. The insights and analytics on the Organic Sulfur Market span several pages. These are covered in numerous sections, including, drivers and restraints, challenges and opportunities, regional segmentation and opportunity assessment,
GLA Supplements Market Key Players, SWOT Analysis, Dynamics, Drivers, Key Indica …
Fact.MR has adopted multi-disciplinary approach to shed light on the GLA Supplements during the historical period. The study presents a deep-dive assessment of the current growth dynamics, major avenues in the estimation year, and key prospects over the forecast period 2018-2028. The insights and analytics on the GLA Supplements Market span several pages. These are covered in numerous sections, including, drivers and restraints, challenges and opportunities, regional segmentation and opportunity
Global Electrotechnical Paper Market to Create an Absolute Dollar Opportunity of …
The recently published market study by Fact.MR highlights the current trends that are expected to influence the dynamics of the Electrotechnical Paper Market in the upcoming years. Click here to Get Complete Synopsis of the Report – https://www.factmr.com/report/1956/electrotechnical-paper-market The report introspects the supply chain, cost structure, and recent developments pertaining to the Electrotechnical Paper Market in the report and the impact of the COVID-19 on these facets of the market. Further,
Global Dibenzyl Toluene Marke to Expand 1.4X by 2030 end | Eastman Chemicals, Ar …
The recently published market study by Fact.MR highlights the current trends that are expected to influence the dynamics of the Dibenzyl Toluene Market in the upcoming years. Click here to Get Complete Synopsis of the Report - https://www.factmr.com/report/4843/dibenzyl-toluene-market The report introspects the supply chain, cost structure, and recent developments pertaining to the Dibenzyl Toluene Market in the report and the impact of the COVID-19 on these facets of the market. Further,
More Releases for NIH
NIH Awards MoBiTec's Partner BellBrook Labs Phase II Grant
NIH Awards MoBiTec's Partner BellBrook Labs Phase II Grant to Develop HTS Assays Targeting the cGAS-STING Pathway for Autoimmune Diseases and Cancer. The National Institutes of General Medical Sciences (NIGMS) recently awarded BellBrook Labs a $1 million phase II Small Business Innovative Research (SBIR) grant to develop new assays to detect cyclic GMP-AMP (cGAMP) levels in biological samples. The assays will be used to discover, develop, and monitor new treatments for
The National Institutes of Health (NIH) Awards Adelphi University Professors Nea …
The National Institutes of Health (NIH) has awarded Adelphi University Associate Professors Brian Stockman, Ph.D. and Melissa VanAlstine-Parris, Ph.D., both in the Department of Chemistry, a federal grant for $310,934. One of the main goals of the project is to immerse undergraduate students into cutting-edge scientific research including hands-on use of NMR spectroscopy instrumentation, medicinal chemistry and Trichomonas vaginalis cell biology. The award became active on June 1, 2017 and
NIH and Themis Bioscience Announce the Initiation of a Clinical Trial of a Chiku …
A prophylactic vaccine candidate against Chikungunya fever developed with proprietary technology of Themis Bioscience GmbH will be tested in a clinical trial sponsored by the U.S. National Institutes of Health (NIH). The vaccine, developed by Themis, is based on a standard measles vaccine as a vaccination vector and hence offers an excellent safety profile. It already showed high seroconversion rates in the preceding Phase I clinical trial: 100 percent of
Agenda Released for Superbugs USA: PAHO/WHO, NIH, AstraZeneca, Pfizer and BARDA …
SMi have announced that a brochure has been released for Superbugs & Superdrugs USA, taking place on November 14th & 15th 2016 in Iselin, New Jersey. Aiming to provide solutions in funding drug development projects, as well as guidance on antibiotic alternatives and updates on global initiatives to fight infectious diseases, the agenda will look to arm attendees with an effective toolkit of ideas to fight the global attack against bacteria's
Dr. James Gulley - NCI, NIH to speak at the Cancer Immunotherapy Congress in Bos …
Dr. James Gulley, an internationally recognized expert in cancer immunotherapy has joined the speaker panel for the Cancer Immunotherapy Congress organized by Markets and Markets Conferences. The congress scheduled for 19th – 20th May 2016 in Boston, USA, will gather scientists, academicians and professionals from Pharmaceutical, Bio-pharmaceutical, Bio-technology companies and Research institutes working in Drug Discovery, Drug Screening, Oncology R&D, Cancer Immunotherapy/ Immuno-oncology and Immunotherapy R&D. Dr. Gulley serves within
Immunetics Awarded $2.4 Million NIH Grant for Clinical Trials of New Blood Test …
Immunetics, Inc. today announced it has been awarded a $2.4 million, 3-year Phase II SBIR grant by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health (NIH), to support clinical trials of the company's new confirmatory test for Chagas’ disease, a serious and potentially fatal parasitic infection. Chagas' disease is endemic in large parts of Latin America, where it affects up to 11